Related Experiment Videos
Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis
Insights
Oral anticoagulation with warfarin significantly reduces recurrence in patients with calf-vein thrombosis. A 3-month treatment course appears sufficient to prevent further thrombotic events.
Area of Science:
- Vascular Medicine
- Hematology
- Clinical Thrombosis
Background:
- Calf-vein thrombosis (CVT) is a significant vascular condition.
- The necessity of long-term anticoagulation for CVT remains a clinical question.
Purpose of the Study:
- To evaluate the efficacy of oral anticoagulation in preventing recurrent thrombosis in patients with symptomatic calf-vein thrombosis.
Main Methods:
- A randomized controlled trial involving 51 patients with CVT.
- Comparison between warfarin treatment for 3 months versus no oral anticoagulation.
- Initial heparin therapy and compression stockings for all participants.
- Monitoring via serial isotope tests, physical examination, and repeat phlebography if recurrence suspected.
Main Results:
- Significantly fewer recurrences in the warfarin group (0%) compared to the non-warfarin group (29%) within the first 3 months (p < 0.01).
- Recurrences in the non-warfarin group included proximal extension and pulmonary embolism.
- After 1 year, 96% of warfarin patients remained recurrence-free versus 68% of non-warfarin patients (p < 0.02).
Conclusions:
- Oral anticoagulants are recommended for all patients presenting with symptomatic calf-vein thrombosis.
- A 3-month duration of oral anticoagulant therapy appears effective in preventing recurrent venous thromboembolism.
Abstract:
The need for oral anticoagulation in patients with calf-vein thrombosis was examined in a randomised study of 51 patients, of whom 23 received warfarin for 3 months and 28 did not. Both groups received an initial course of heparin and all wore compression stockings. Progress was monitored by the use of serial isotope tests and physical examination. Phlebography was repeated if recurrence was suspected. During the first 3 months, 8 patients in the non-warfarin group (29%) had recurrences compared with none in the warfarin group (p less than 0.01). 5 patients had recurrence with proximal extension and 1 patient had a pulmonary embolus. After 1 year, 22 out of 23 patients in the warfarin group had not had a recurrence, compared with 19 out of 28 (p less than 0.02). The findings indicate that oral anticoagulants should be given to all patients with thrombi that produce symptoms. Treatment for 3 months seems to be sufficient.